Voices
Integrating 177Lu-PSMA-617 Into the Management of mCRPC – Duke University Health System
Duke University Health System/LinkedIn

Integrating 177Lu-PSMA-617 Into the Management of mCRPC – Duke University Health System

Duke University Health System shared a post on LinkedIn:

“This CME activity, featuring genitourinary medical oncologist Dillon Cockrell, reviews key clinical considerations for integrating lutetium-177 (177Lu)-prostate-specific membrane antigen (PSMA)-617 into the management of metastatic castration-resistant prostate cancer (mCRPC).

Claim your credits.”

Integrating 177Lu-PSMA-617 Into the Management of mCRPC – Duke University Health System

More posts about prostate cancer.

 

cancer Dillon Cockrell Duke University Health System mCRPC OncoDaily Oncology prostate cancer